cyrilzakka/clinical-trials huggingface dataset:
Visual Perception in Schizophrenia

This study aims to identify novel markers of psychosis using electroencephalography (EEG).


Eligibility Criteria:
Inclusion Criteria:

* All Subjects
* Aged 18-65
* 20/32 visual acuity or better (using in-house optical correction, if necessary)
* An ability to speak English well enough to complete study assessments and to consent to the study
* Subjects with Schizophrenia-Spectrum Disorder
* Meets DSM-5 diagnostic criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder as confirmed by the Structured Interview for DSM-5 (SCID-5).
* Subjects with Bipolar Disorder
* Meets DSM-5 diagnostic criteria for bipolar disorder (type I, II, or unspecified) as confirmed by the Structured Interview for DSM-5 (SCID-5).

Exclusion Criteria:

* All subjects
* Presence of characteristics that could impair one's ability to comprehend the nature of the study, provide informed consent, or understand the assessment questions, including the following:

  * Subject cannot read and understand the instructions well enough to complete the tasks or cannot provide informed consent.
  * Intellectual impairment (WRAT-5 score \< 70) (at the discretion of experimenter);
  * Actively intoxicated, as shown via patient self-report or staff report;
  * Substance use disorder in the past 3 months;
  * Subject considered high risk for suicidal acts (i.e., active suicidal ideation as determined by clinical interview OR any suicide attempt in 30 days prior to screening);
  * Subject violence (involving severe/lethal means or violence occurring in prior 6 months) or extreme agitation.
  * Being in a current manic state
  * Head injury with loss of consciousness greater than 10 minutes (at the discretion of the experimenter).
  * Subject has had electroconvulsive therapy (ECT) in the past 8 weeks;
  * Diagnosed with a neurological condition (tumor, stroke, brain injury) or neurological disorder, including seizure disorders. Diagnosed with pervasive developmental disorder (phone screen or medical records)
  * Lazy eye or squint or other known ocular pathology
* Healthy Control Subjects
* Any lifetime psychotic disorder or history of psychiatric hospitalization (self disclosure);
* Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days (self-disclosure); iii. First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder.
* Case-match Control Non-ill Subjects
* Any lifetime psychotic disorder (as assessed by SCID/or SSD);
* Recurrent depressive episodes or being in a current depressive episode (as assessed by SCID/or SSD)
* Persistent threshold psychotic symptoms
* History of psychiatric hospitalization;
* Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days
* First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder.
* Bipolar Subjects
* Persistent threshold psychotic symptoms
Ischemic Heart Disease in Male With Prostate Adenocarcinoma

The purpose of the study: to increase the efficiency of diagnosis, treatment and prediction of the course of coronary heart disease in patients with adenocarcinoma of the prostate gland, depending on the hormonal status by determining the cardiovascular risk factors, factors of angiogenesis, structural and functional state of the heart, coronary vessels, kidney damage and their pharmacological correction.

Research methods:

1. general-clinical examination
2. Laboratory methods:

   * estimation of the generally accepted laboratory parameters
   * determination of blood lipid profile
   * Determination of the level of highly sensitive CRP by the method of immuno-enzyme analysis,
   * determination of the level of proteinuria, creatinine by the method of immuno-enzyme analysis with the subsequent calculation of GFR
   * determination of the level of insulin by the method of immuno-enzyme analysis with the subsequent calculation of indices of insulin resistance,
   * determination of the level of blood testosterone by the method of immuno-enzyme analysis,
   * determination of the levels of vascular-endothelial growth factor, angiosetamine by the immuno-enzyme assay,
3. Echo-doppler examination of vessels (endothelium-dependent vasodilatation with reactive hyperemia, determination of the thickness of CIM, GPI)
4. Ultrasound examination of the main vessels of the head and neck
5. ECG
6. Daily monitoring of BP
7. CT-angiographic examination of coronary vessels with the definition of the index of calcification
8. Statistical methods

Eligibility Criteria:
Inclusion Criteria:

* men aged 45-75 years
* presence of verified diagnosis of adenocarcinoma of the prostate gland,
* stable antitumor therapy for 6 months, verified diagnosis of CAD,
* stable cardiological therapy for the past 3 months,
* voluntary informed consent to participate in the study.

Exclusion Criteria:

* age older than 75 years,
* female sex,
* metastatic lesion,
* chronic heart failure of the III-IV functional class (FC),
* arrhythmias that cause hemodynamic impairment and require antiarrhythmic correction (including ventricular arrhythmias of high gradation, atrial flutter , paroxysmal tachycardia, sinus node weakness syndrome, 2-3-degree AV block),
* AMI, acute cerebrovascular accident,
* diabetes mellitus (insulin-dependent diabetes mellitus) with a level of NvA1s\> 7%, hyperthyroidism and hypothyroidism level of TSH\> 10 mD / L, chronic renal failure (GFR \<30 ml / min / 1.73 m2),
* acute cardiac and renal insufficiency,
* obesity 4 degrees,
* cachexia.
Smartphone Based Tele-rehabilitation on Functional Capacity and Sleep Quality Among Coronary Heart Disease Patients.

To determine the effectiveness of smartphone based tele-rehabilitation on functional capacity and sleep quality among coronary heart disease patients.


Eligibility Criteria:
Inclusion Criteria:

* Both Male \& Female
* Age 20-69 years
* Participants should have a documented diagnosis of CAD, confirmed by a medical professional.
* Individuals with a history of myocardial infarction (heart attack), angina, or evidence of significant coronary artery stenosis.
* Stable CAD who are not experiencing acute coronary events, such as recent heart attacks or unstable angina.

Exclusion Criteria:

* Acute illness
* Uncontrolled hypertension
* Uncontrolled metabolic disease
* Bone fracture in the last 6 months
* Neurological diseases that limit the ability to ambulate or stand from a chair
* MSK disease
* Severe cardiovascular complications such as heart failure with reduced ejection fraction, severe arrhythmias.
* Patients with unstable conditions or cardiac episodes.
* Ejection fraction \< 40%
Tazocin Intervention Study

1. To determine the value of using piperacillin/tazobactam in reducing the cases of extended spectrum beta lactamases (ESBL) producing E. coli or K. pneumoniae colonization and infection.
2. To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, both pre-and post-intervention in the selected medical centers.


Eligibility Criteria:
Inclusion Criteria:

* All patients admitted or transferred to the ICU/pulmonary/Infection units
* Patients of either sex, 18 years of age or older Patients who stay in units less than 48 hours will not be enrolled.
Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis

The aim of the project is to determine whether daylight activated photodynamic therapy is effective in treating cutaneous leishmaniasis caused by L. major and L. tropical.

PDT is classically performed as a two-step procedure in which MAL application to the lesion constitutes the first step, and PpIX activation by light of appropriate wavelength from an artificial light source constitutes the second step. Based on the knowledge that red and blue light required to activate PpIX are part of the daylight spectrum, the investigators postulated that effective PpIX activation can be obtained by exposure of the MAL treated lesions to daylight thus substantially simplifying the PDT procedure by omitting the 3 hour incubation period and the subsequent exposure to artificial light. In accord, in a recent study the investigators showed that daylight-activated PDT (DA-PDT) was as effective as conventional MAL-PDT in treating precancerous actinic keratoses lesion. Furthermore the investigators found that DA-PDT is significantly less painful than conventional MAL-PDT.

The investigators now propose to study the efficacy of DA-PDT in the treatment of cutaneous leishmaniasis. DA-PDT has obvious advantages to conventional leishmania treatment forms:

As opposed to most of the available treatment options, DA-PDT is a self-administered procedure that does not require the assistance of medical personnel. Secondly, judged by our experience with MAL-PDT, only few treatment sessions are required for effective parasite killing as opposed to the prolonged procedures usually required for treatment of leishmaniasis. Third, PDT has the far the best safety profile of all available treatment options.


Eligibility Criteria:
Inclusion Criteria:

* At least 2 skin lesions with leishmania caused by L. major or L. tropica

Exclusion Criteria:

* Pregnant or lactating women
Companion Robotic Pets and Older Adults

This research will assess the effect of companion robotic pets on the wellbeing of older adults and their family caregivers.

Social robot pets have been shown to have a positive impact on age-related physical, cognitive, emotional, and social challenges that affect independence and quality of life. These "pets" are designed to interact with people as a real pet might. They purr when stroked, make eye contact, have a heartbeat, turn toward a person when touched, are warm, and appear lifelike. Does introduction of such a pet reduce loneliness or promote engagement in older adults with cognitive or physical disability?

This research will determine if:

1. Older adults with disabilities engage with such robotic companions;
2. Placing a robotic pet in a home enhances mood and positive affect in older people;
3. Caregivers to these adults find the robots beneficial for their own mood and time use.

In a single-blind randomized controlled trial over 6-8 weeks, we hypothesize that older adults in the intervention arm will engage with the pets and show benefit in mood as reported by family caregivers.

Eligibility Criteria:
Inclusion Criteria:

1. Participating in Family Caregiver Support Program or OPTIONS Program administered by Allegheny County Area Agency on Aging
2. Provide unpaid family or friend caregiver support for at least 6 months
3. Older person aged 50+
4. Able to provide verbal informed consent

Exclusion Criteria:

1. Uncomfortable with robot pet companion in home
2. Family Caregiver \< 18 years age
PT vs no PT Following THA

The purpose of this study is to determine if outpatient physiotherapy results in improved and/or more rapid achievement of functional outcomes and quality of life in comparison to those patients who do not undergo outpatient physiotherapy after total hip arthroplasty


Eligibility Criteria:
Inclusion Criteria:

* Any patient undergoing unilateral primary total hip arthroplasty with age \> 60

Exclusion Criteria:

* Post-traumatic osteoarthritis
* Rheumatoid arthritis or other peripheral inflammatory disease
* Avascular necrosis
* Revision or conversion THA
* Post-septic osteoarthritis
* Patients discharged to a rehabilitation unit or other form of respite care such as a skilled nursing facility, acute rehabilitation center, convalescent home, long-term care facility or nursing home
IMRT Versus IMPT With Concurrent Chemotherapy for Locally Advanced Anal Canal Cancer

The standard practice in management of carcinoma of anal canal is to treat patients with radiotherapy using the IMRT technique along with chemotherapy. It is known that while IMRT has reduced treatment related side effects as compared to the older radiation techniques, reducing these side effects further still remains a major challenge.

These side-effects include gastrointestinal (diarrhea, altered bowel habits, weight loss, bleeding, obstruction), genitourinary (difficulties in passing urine, passing blood in urine, difficulty in holding urine) and hematologic toxicities (anemia, low platelet count and increased predisposition to infections).

Proton therapy (IMPT) is a form of radiation treatment in which high doses can be delivered within the tumor while the surrounding normal tissues receive a lesser radiation dose. It is believed that these physical properties of proton therapy may help reduce the side effects of treatment.

Patients will be randomly assigned to either receive IMRT or IMPT based treatment so as to see whether it is possible to reduce the acute treatment related toxicities. In this study, there is a 66.7% chance that the patient will get IMPT based treatment, which may be able to reduce the toxicities.


Eligibility Criteria:
Inclusion Criteria:

1. Age \> 18 and \< 80 years of age
2. Histologically confirmed squamous cell carcinoma of the anal canal or distal rectum
3. The patients may have TNM stage T1-2 N+M0 or T3-4 N0-1c M0 (UICC 8th edition)
4. Involvement of lower para-aortic lymph nodes (till renal hilum) as the only site of disease extension on PET CECT may also be included as they receive radical chemoradiation as standard treatment.
5. WHO or ECOG performance status 0-1
6. HIV testing is known and HPV (P16) testing done on tissue sample.
7. With suitable blood test values for standard concurrent chemotherapy (Hb \> 10 mg/dL, ANC \> 1.5 cells/mm3, Platelets \> 100,000 cells/mm3, Creatinine \< 1.5 x ULN, Bilirubin \< 3 x ULN, ALT \< 3 x ULN) as deemed by a medical oncologist in team.
8. The patient must be expected to tolerate the treatment and be compliant for follow up.
9. No contradiction for chemoradiation such as inflammatory bowel disease, pregnancy, etc.
10. Willing to consent to participate in the study.

Exclusion Criteria:

1. Two or more synchronous primary cancers.
2. When prosthetic materials (e.g. hip prostheses) are present close to the target volume, it must be considered if this may introduce uncertainties in dose calculations, which may affect the treatment planning process.
3. Ulcerative colitis or any other histologically confirmed inflammatory bowel disease.
4. Poor reliability for follow-up and treatment completion.
Safety of Ascending Doses of Niclosamide (UNI911 INHALATION) in Healthy Volunteers

This is a Phase 1 Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in Preparation for Evaluation in Adults with COVID-19

This is a Phase 1 Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in Preparation for Evaluation in Adults with COVID-19

64 subjects will be sequentially enrolled to receive dosage of UNI911 INHALATION or placebo. 4 sentinel subjects (one per cohort 1, 2 ,3 and 4 ) will be treated in an open-label manner to confirm the safety of each dose sequentially. 40 subjects will be randomly assigned (3:1) to either active or placebo. For the last 2 cohorts, a total of 20 healthy volunteers will be enrolled to receive multiple doses of UNI911 INHALATION.

Eligibility Criteria:
Inclusion Criteria (main ones):

1. Signed Informed Consent Form (ICF)
2. Male or non-pregnant and non-lactating female who is abstinent or agrees to use effective contraceptive methods throughout the course of the study. Females must have a negative urine beta-human chorionic gonadotropin hormone (hCG) pregnancy test prior to dosing. (Women who are postmenopausal or who had tubal ligation/hysterectomy do not need to have a pregnancy test done and do not need to agree to use contraception.)
3. ECG without clinically significant abnormalities (including QTcF \< 450 ms)
4. Age ≥ 18 and \< 65 years at the time of signing ICF
5. Normally active and in good health by medical history and physical examination
6. Minimum 80% of predicted lung function, including FEV1 after beta2-agonist, TLC, DCO, and CPET with pulse oximetry
7. Chest X-ray without clinically significant abnormalities

Exclusion Criteria (main ones):

1. Enrollment in an UNI911 study in the previous 6 months
2. Clinically significant allergy (as judged by the investigator) or history of significant adverse reaction to niclosamide or related compounds, to any of the excipients used.
3. Underlying condition that may interfere with inhalation of the IP
4. Current acute or chronic condition (incl. COPD, asthma, or other severe respiratory disease, CV disease, diabetes mellitus, obesity, malignant and autoimmune diseases) unless considered clinically irrelevant and stable by the investigator
5. Renal impairment (eGFR \< 60 mL/min/1.73m2) or hepatic impairment (as judged by the investigator)
The Femscope Calm Collect Device

The goal of this clinical trial is to determine if cervical cells collected by the Femscope Calm Collect Device in women (sex assigned at birth) of adult age are the same quality and quantity as the cervical cells collected by the traditional brush method for cervical cancer screening. The main questions it aims to answer are:

1. Increase the number of women who get screened for cervical cancer.
2. Improve patient acceptance of getting cervical screening on a routine basis.
3. Decrease pain and discomfort for patients having a PAP smear procedure.

Participants will

* Have two vaginal exams to collect cervical cells.
* State decreased pain and discomfort for patients having a PAP smear procedure.
* The Femscope Calm Collect Device (FCCD) will be more comfortable for the patient as measured by a patient satisfaction survey comparing the FCCD and the traditional speculum method of obtaining cervical cells.

The FemScope Calm Collect Device is a novel medical device intended for vaginal inspection, cervical cancer screening, rectal cancer screening, and discharge/cell retrieval. The device allows for increased comfort (emotionally and physically) to the patient while meeting the requirements of a genital exam.

The FemScope system includes a light and camera, enabling visualization of the vagina and cervix and display on a screen. It also provides brushing/retrieval means, allowing the provider to obtain necessary cervical cells for a pap smear, HPV, and specimens needed for sexually transmitted disease (STI) testing. The system will also allow the direct visualization of rectal tissue sampled for human papillomavirus/rectal cancer. The system is designed to replace the speculum, provide the tools needed to perform comprehensive pelvic and topical rectal exams, provide cervical cancer screens, and be cost-competitive with existing speculum and tissue swab systems. It is simple and easy to use. The device comprises a reusable base portion, a removable protective sleeve, and a single-use cell retrieval cap for improved cost-effectiveness.

This instrument will revolutionize women's health care, replacing the antiquated speculum examination with modern scopes like those used to visualize many other portions of the human body. Having the instrument designed to facilitate exams in the LGBTQIA community is sorely needed and will improve gynecologic and genital examinations in that community

Eligibility Criteria:
Inclusion Criteria:

- Healthy female ages 21-45 with female reproductive organs present at the time of study.

Exclusion Criteria:

* Pregnancy
* Menopausal
* Age less than 21 years
* Age of 46+ years
* History of reproductive cancer
* Hysterectomy
Learning in Stroke

After a stroke, plasticity occurs in the brain from microscopic to network level with positive but also negative consequences for functional recovery. Why post-stroke plasticity takes a beneficial or a maladaptive direction is still incompletely understood. Because the biological mechanisms underlying sensorimotor learning parallel those observed during recovery, learning mechanisms could be potential modifiers of post-stroke neuroplasticity and have a discrete mal-/adaptive impact on the recovery of sensorimotor function. This project seeks to further the understanding of the link between brain circuits that control the integration of new information during procedural learning in the injured brain and those circuits that are involved in adaptive plastic changes during recovery of sensorimotor function post-stroke. The project's methodological approach will allow the characterization of procedural learning-related neural network dynamics based on functional magnetic resonance imaging (MRI) in human volunteers with and without neurologically impairment post-stroke. Through multivariate integration of behavioral and biological descriptors of sensorimotor recovery, the project will investigate the association between motor learning-related network dynamics and descriptors of recovery.


Eligibility Criteria:
INCLUSION CRITERIA

For all participants:

* adult volunteers (age ≥18 years)
* right-hand dominance as defined by the Edinburgh Handedness Inventory

Stroke-specific inclusion criteria:

* ischemic or hemorrhagic lesion
* subcortical or cortical tissue involvement
* chronic phase (\>6 months) after their index lesion
* voluntary whole-hand grip force (MRC, Medical Research Council scale for muscle force ≥2)
* repeated release (standardized as a reduction of 50% of maximum voluntary contraction measured with a dynamometer)

EXCLUSION CRITERIA

For all participants:

* Presence of any MRI risk factors
* substance use disorder
* psychotic disorders

Stroke-group specific exclusion criteria:

* Primary intracerebral hematoma
* subarachnoid hemorrhage
* bi-hemispheric or cerebellar strokes
* other concomitant neurological disorders affecting upper extremity motor function
* documented history of dementia before or after stroke
* severe aphasia, particularly of receptive nature (NIHSS Language subsection ≥2), affecting their ability to understand the purpose of the study and give informed consent
* uncontrolled hypertension despite treatment
* intake of tricyclic anti-depressants or neuroleptic medication.
Rural Libraries Promoting Walking and Walkability in Their Rural Communities

The investigators will randomize 20 rural libraries to implement either a group-based walking (standard approach) or a group-based walking combined with a civic engagement program (combined approach). Each rural library will enroll between 15-20 participants. The investigators will compare the change in physical activity between participants in each group.

The goals of this study are:

1. Increase the capacity of rural libraries to deliver evidence-based health promotion programs
2. Compare the effects of a group-based walking program with a combined group-based plus civic engagement program on physical activity, cardiovascular fitness and collective efficacy among rural residents.
3. Evaluate program implementation

Eligibility Criteria:
Inclusion Criteria:

* Age 18 or older
* Inactive (defined as engaging in physical activity \<3 days per week)
* Ability to walk for at least 20 minutes
* Living within the rural community served by the local library
* Ability to travel to the local library/location of walking group.

Exclusion criteria:

* Participation/intention to participate in other lifestyle modification pro-gram(s)
* Cognitive impairment
* Inability to communicate due to severe uncorrected hearing loss or speech disorder or severe visual impairment (if precludes completion of assessments and/or intervention)